Tirzepatide cuts major cardiovascular risks by 32% compared to sitagliptin in adults with type 2 diabetes and cardiovascular disease, according to a recent population-based cohort study. While providing vital heart protection, real-world data and clinical trials underscore that interrupting treatment can rapidly erode these metabolic gains.
The dual incretin agonist tirzepatide—which targets both glucose-dependent insulinotropic peptide and glucagon-like peptide 1 receptors—continues to draw intense scrutiny from clinicians mapping its systemic effects. Beyond managing blood sugar and reducing weight, recent data show the medication delivers profound protective benefits for the cardiovascular system. Yet, as researchers map these heart benefits, parallel findings reveal a precarious catch: stopping the medication triggers a swift metabolic whiplash that can quickly erase hard-won gains.
Real-World Data Links Tirzepatide to Lower Heart Risk
The investigation emulated trial designs by comparing 35,353 patients initiating tirzepatide against 17,618 patients taking sitagliptin as a validated active placebo proxy, according to the emulated trial design using healthcare claims data.
At the one-year mark, major adverse cardiovascular events occurred in 2.9% of patients taking tirzepatide compared with 4.4% of those on sitagliptin. This translates to an approximate 32% lower risk of major cardiovascular events for the tirzepatide cohort. In practical terms, for every 70 people treated with tirzepatide instead of sitagliptin, one additional major cardiovascular event was prevented.
When examining individual components of cardiovascular risk, researchers found that tirzepatide was specifically linked to a lower hazard of myocardial infarction and all-cause mortality, though ischaemic stroke rates showed no meaningful difference between the two treatments. Beyond cardiac endpoints, the observational data noted a marked reduction in infections requiring hospitalization—preventing one such hospital admission for every 48 patients treated—alongside fewer infection-related deaths.
Weighing Active Comparators in Clinical Trials
While observational claims data provide a window into routine clinical practice, head-to-head randomized trials offer a different lens on efficacy. Findings presented at the American College of Cardiology’s annual meeting and published simultaneously in JAMA Cardiology analyzed a secondary trial involving more than 13,000 participants with type 2 diabetes and pre-existing cardiovascular disease. Patients in that study received up to 15 mg weekly of tirzepatide or 1.5 mg weekly of dulaglutide for nearly four years on average.
The analysis showed that serious complications including heart attack, stroke, or cardiovascular death occurred in 12.2% of participants taking tirzepatide versus 13.1% taking dulaglutide, establishing that tirzepatide was effective but not statistically superior on that specific composite metric. However, when Cleveland Clinic researchers assessed six major complications—incorporating heart attack, stroke, coronary procedures like stenting, heart failure, kidney failure, and all-cause mortality—the cumulative incidence dropped to 23.7% for tirzepatide compared to 27.4% for dulaglutide.
The Hidden Risks of Interrupting Treatment
While clinical data establish the protective capabilities of incretin-based therapies, Washington University School of Medicine researchers highlighted a critical vulnerability: the rapid erosion of cardiovascular benefits when patients discontinue treatment.
Following a study tracking more than 333,000 U.S. veterans with type 2 diabetes over three years, investigators found that interrupting or stopping GLP-1 therapy for as little as six months elevated the risk of heart attack, stroke, and death. The longer the gap in treatment, the bigger the jump in risk—up to a 22% increase for heart attack, stroke and death after two years off GLP-1s.
There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop. Many quit after a few months because of cost, side effects or shortages. When they stop, it’s not just weight that comes back; they experience a resurgence in inflammation, blood pressure, and cholesterol. Weight regain is visible; the metabolic reversal is not, said Ziyad Al-Aly, MD, a WashU Medicine clinical epidemiologist and chief of the Research and Development Service at the VA Saint Louis Health Care System.
The analysis noted that restarting the medication only partially restored cardiovascular protection, demonstrating that discontinuation leaves a lasting metabolic scar.
